Short Interest in Caribou Biosciences, Inc. (NASDAQ:CRBU) Grows By 24.4%

Caribou Biosciences, Inc. (NASDAQ:CRBU - Get Free Report) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 9,490,000 shares, a growth of 24.4% from the April 30th total of 7,630,000 shares. Currently, 11.7% of the company's shares are sold short. Based on an average daily trading volume, of 1,040,000 shares, the days-to-cover ratio is currently 9.1 days.

Institutional Trading of Caribou Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ancora Advisors LLC boosted its holdings in shares of Caribou Biosciences by 16.0% during the fourth quarter. Ancora Advisors LLC now owns 58,000 shares of the company's stock valued at $92,000 after acquiring an additional 8,000 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Caribou Biosciences by 28.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 35,848 shares of the company's stock worth $57,000 after purchasing an additional 8,008 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Caribou Biosciences by 4.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 176,654 shares of the company's stock worth $281,000 after purchasing an additional 8,199 shares in the last quarter. MetLife Investment Management LLC increased its holdings in shares of Caribou Biosciences by 60.0% during the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company's stock valued at $39,000 after purchasing an additional 9,148 shares during the period. Finally, American Century Companies Inc. raised its stake in shares of Caribou Biosciences by 9.2% during the fourth quarter. American Century Companies Inc. now owns 159,822 shares of the company's stock valued at $254,000 after purchasing an additional 13,421 shares in the last quarter. 77.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and issued a $3.00 price target (down previously from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th.

Caribou Biosciences Stock Down 3.5%

CRBU stock traded down $0.04 during trading on Thursday, hitting $1.09. 446,435 shares of the company's stock traded hands, compared to its average volume of 1,401,678. The stock has a market capitalization of $101.38 million, a price-to-earnings ratio of -0.66 and a beta of 2.44. Caribou Biosciences has a 52 week low of $0.66 and a 52 week high of $3.00. The stock has a fifty day moving average price of $0.89 and a two-hundred day moving average price of $1.30.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.43). Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The business had revenue of $2.35 million during the quarter, compared to the consensus estimate of $1.48 million. As a group, equities research analysts expect that Caribou Biosciences will post -1.64 EPS for the current fiscal year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.